258,388 Shares in Inhibrx, Inc. (NASDAQ:INBX) Acquired by Millennium Management LLC

Millennium Management LLC purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 258,388 shares of the company's stock, valued at approximately $3,979,000. Millennium Management LLC owned approximately 1.78% of Inhibrx as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in INBX. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in Inhibrx during the 4th quarter worth approximately $348,000. Deutsche Bank AG acquired a new stake in shares of Inhibrx in the fourth quarter valued at $302,000. Exchange Traded Concepts LLC acquired a new stake in shares of Inhibrx in the fourth quarter valued at $148,000. Bank of New York Mellon Corp purchased a new position in Inhibrx in the fourth quarter valued at $792,000. Finally, Barclays PLC acquired a new position in Inhibrx during the 4th quarter worth $289,000. Hedge funds and other institutional investors own 82.46% of the company's stock.

Inhibrx Stock Performance

Shares of NASDAQ:INBX traded up $0.57 during trading hours on Tuesday, reaching $13.53. The stock had a trading volume of 78,775 shares, compared to its average volume of 116,019. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $18.95. The firm's 50 day moving average is $12.36 and its 200-day moving average is $13.43. The stock has a market capitalization of $195.86 million and a price-to-earnings ratio of 0.12.

Inhibrx (NASDAQ:INBX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($2.55) by ($0.25). Analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current year.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx in a research report on Thursday, May 15th.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.